Application No. Not Yet Assigned Paper Dated: January 12, 2004 In Reply to USPTO Correspondence of N/A Attorney Docket No. 0470-050079

## **AMENDMENTS TO THE ABSTRACT**

After the claims, please insert a new <u>Abstract Of The Disclosure</u>, which is attached hereto as a separately typed page.

## PHARMACEUTICAL COMPOSITION COMPRISING ESTETROL DERIVATIVES FOR USE IN CANCER THERAPY

The present invention relates to a method of treating or preventing estrogen-sensitive tumours in a mammal, said method comprising the administration of a therapeutically effective amount of an estrogenic component to said mammal, wherein the estrogenic component is selected from the group consisting of: substances represented by the following formula

$$R_1$$
 OH OH OH  $R_2$   $R_3$   $R_4$ 

in which formula R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> independently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1-5 carbon atoms; precursors capable of liberating a substance according to the aforementioned formula when used in the present method; and mixtures of one or more of the aforementioned substances and/or precursors.

The estrogenic component according to the invention does not have undesirable proliferative effects on breast and/or endometrial tissue and displays sufficient estrogenicity to prevent that its administration will lead to hypoestrogenism and/or climacteric complaints.